Table of Contents
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Antibody Fragments Market, by Region, 2019-2029 (USD Billion)
1.2.2. Antibody Fragments Market, by Product, 2019-2029 (USD Billion)
1.2.3. Antibody Fragments Market, by Application, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Antibody Fragments Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Antibody Fragments Market Dynamics
3.1. Antibody Fragments Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Increase in chronic conditions such as cancer, immunodeficiency, and others
3.1.1.2. Increasing expenditure on healthcare activities
3.1.2. Market Challenges
3.1.2.1. Some obstacles are associated with the purification of antibody fragments
3.1.2.2. Imposition of stringent regulatory norms for the approval of antibody fragments
3.1.3. Market Opportunities
3.1.3.1. Growing investment in the R&D activities
3.1.3.2. Rising number of clinical developments for antibody fragments and related products for serious diseases
Chapter 4. Global Antibody Fragments Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Investment Adoption Model
4.5. Analyst Recommendation & Conclusion
4.6. Top investment opportunity
4.7. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Antibody Fragments Market, by Product
6.1. Market Snapshot
6.2. Global Antibody Fragments Market by Product, Performance - Potential Analysis
6.3. Global Antibody Fragments Market Estimates & Forecasts by Product, 2019-2029 (USD Billion)
6.4. Antibody Fragments Market, Sub Segment Analysis
6.4.1. FAB
6.4.2. scFv
6.4.3. sdAb
6.4.4. Others
Chapter 7. Global Antibody Fragments Market, by Application
7.1. Market Snapshot
7.2. Global Antibody Fragments Market by Application, Performance - Potential Analysis
7.3. Global Antibody Fragments Market Estimates & Forecasts by Application, 2019-2029 (USD Billion)
7.4. Antibody Fragments Market, Sub Segment Analysis
7.4.1. Cancer
7.4.2. Immunodeficiency
7.4.3. Others
Chapter 8. Global Antibody Fragments Market, Regional Analysis
8.1. Antibody Fragments Market, Regional Market Snapshot
8.2. North America Antibody Fragments Market
8.2.1. U.S. Antibody Fragments Market
8.2.1.1. Product breakdown estimates & forecasts, 2019-2029
8.2.1.2. Application breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Antibody Fragments Market
8.3. Europe Antibody Fragments Market Snapshot
8.3.1. U.K. Antibody Fragments Market
8.3.2. Germany Antibody Fragments Market
8.3.3. France Antibody Fragments Market
8.3.4. Spain Antibody Fragments Market
8.3.5. Italy Antibody Fragments Market
8.3.6. Rest of Europe Antibody Fragments Market
8.4. Asia-Pacific Antibody Fragments Market Snapshot
8.4.1. China Antibody Fragments Market
8.4.2. India Antibody Fragments Market
8.4.3. Japan Antibody Fragments Market
8.4.4. Australia Antibody Fragments Market
8.4.5. South Korea Antibody Fragments Market
8.4.6. Rest of Asia Pacific Antibody Fragments Market
8.5. Latin America Antibody Fragments Market Snapshot
8.5.1. Brazil Antibody Fragments Market
8.5.2. Mexico Antibody Fragments Market
8.6. Rest of The World Antibody Fragments Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Pfizer Inc.
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Albynx
9.2.3. Novartis AG
9.2.4. Genentech, Inc.
9.2.5. AbbVie Inc.
9.2.6. Bristol-Myers Squibb Company
9.2.7. Johnson & Johnson Private Limited
9.2.8. Lilly
9.2.9. Takeda Pharmaceutical Company Limited
9.2.10. Sanofi
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption